TRPC6 and Alzheimer disease: Increasing TRPC6 activity by the TRPC6 agonist (hyperforin) dramatically reduced Aβ levels which were a major pathological factor for Alzheimer’s disease and ameliorated cognitive performance (Lu et al., 2018).